A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-407
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

19 Sep 2024 This trial has been completed in Spain (Global end date: 2023-09-14) according to European Clinical Trials Database record.
28 Sep 2023 Status changed from active, no longer recruiting to completed.
22 Sep 2023 This trial has been completed in Hungary (Date of the global end of the trial: 14-Sep-2023), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight